Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1252-1259

  Manetti, Fabrizio ^a   Brullo, Chiara ^b   Magnani, Matteo ^a   Mosci, Francesca ^a   Chelli, Beatrice ^c   Crespan, Emmanuele ^d   Schenone, Silvia ^b   Naldini, Antonella ^a   Bruno, Olga ^b   Trincavelli, Maria Letizia ^c   Maga, Giovanni ^d   Carraro, Fabio ^a   Martini, Claudia ^c   Bondavalli, Francesco ^b   Botta, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ABELSON KINASE; AP 23846; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; ENZYME INHIBITOR; HALIDE; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG;

ARTICLE; CELL FREE SYSTEM; CELL GROWTH; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MOLECULAR DOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA; MODELS, MOLECULAR; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41649083169     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701240c     Document Type: Article

References (29)

1. Nowell, P. C.; Hungerford, D. A. A minute chromosome in chronic granulocytic leukemia. Science 1960, 132, 1497-1501.
2. Rowley, J. D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243, 290-293.
3. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 1999, 340, 1330-1340.
4. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 1990, 247, 1079-1082.
5. Wilson, M. B.; Schreiner, S. J.; Choi, H. J.; Kamens, J.; Smithgall, T. E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002, 21, 8075-8088.
6. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 5, 561-556.
7. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosee, P.; Muller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190-2196.
8. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amlification. Science 2001, 293, 876-880.
9. Walz, C.; Sattler, M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit. Rev. Oncol. Hematol. 2006, 57, 145-164.
10. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7, 129-141.
11. Gumireddy, K.; Baker, S. J.; Cosenza, S. C.; John, P.; Kang, A. D.; Robell, K. A.; Reddy, M. V.; Reddy, E. P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 1992-1997.
12. Martinelli, G.; Soverini, S.; Rosti, G.; Baccarani, M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 2005, 19, 1872-1879.
13. Boschelli, D. H. Dual inhibitors of Src and Abl tyrosine kinases. Drug Des. Rev-Online 2004, 1, 203-214.
14. Schenone, S.; Manetti, F.; Botta, M. Synthetic Src-kinase domain inhibitors and their structural requirements. Anti-Cancer Agents Med. Chem. 2007, 7, 660-680.
15. (a) Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, J.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schimdt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-l-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47, 6658-6661.
16. (b) Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-l- piperazinyl)]-2methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 2006, 49, 6819-6832.
17. (a) Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354, 2531-254).
18. (b) Kolb, E. A.; Gorfick, R.; Houghton, P. J.; Morton, C. L.; Lock, R. B.; Tajbakhsh, M.; Reynolds, C. P.; Maris, J. M.; Keir, S. T.; Billups, C A.; Smith, M. A. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr. Blood Cancer, http://dx.doi.org/10.1002/pbc.21368.
19. U.S. Food and Drug Administration, http://www.fda.gov/bbs/topics/NEWS/ 2006/NEW01400.html (accessed 2006).
20. Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf, C. A., III; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D. R.; Bornmann, W. G.; Clarkson, B.; Dalgarno, D. C.; Sawyer, T. K.; Daley, G. Q. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 9244-9249.
21. Kimura, S.; Naito, H.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Yokota, A.; Kamitsuji, Y.; Kawata, E.; Ashihara, E.; Nakaya, Y.; Naruoka, H.; Wakayama, T.; Nasu, K.; Asaki, T.; Niwa, T.; Hirabayashi, K.; Maekawa, T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106, 3948-3954.
22. Naito, H.; Kimura, S.; Nakaya, Y.; Naruoka, H.; Kimura, S.; Ito, S.; Wakayama, T.; Maekawa, T.; Hirabayashi, K. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk. Res. 2006, 11, 1443-1446.
23. Cheetham, G. M.; Charlton, P. A.; Golec, J. M.; Pollard, J. R. Structural basis for potent inhibition of the Aurora kinases and a T315I multidrug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 2007, 251, 323-329.
24. Manetti, F.; Pucci, A.; Magnani, M.; Locatelli, G. A.; Brullo, C.; Naldini, A.; Schenone, S.; Maga, G.; Carraro, F.; Botta, M. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d] pyrimidines in human leukemia cells. ChemMedChem 2007, 2, 343-353.
25. Grid 22; Molecular Discovery Ltd: Pinner, Middlesex, U.K.
26. (a) Cruciani, G.; Pastor, M.; Guba, W. Volsurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11 (2), S29-S39.
27. (b) Further information at the Volsurf web site: http://www.moldiscovery. com/docs/volsurf.
28. Carraro, F.; Naldini, A.; Pucci, A.; Locatelli, G. A.; Maga, G.; Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Brullo, C.; Fossa, P.; Menozzi, G.; Mosti, L.; Modugno, M.; Tintori, C.; Manetti, F.; Botta, M. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J. Med. Chem. 2006, 49, 1549-1561.
29. Schenone, S.; Brullo, C.; Bruno, O.; Bondavalli, F.; Ranise, A.; Botta, M.; Corradi, V.; Santucci, M. A.; Mancini, M.; Corrado, P.; Crespan, E.; Maga, G. Synthesis of new pyrazolo[3,4-d]pyrimidines Bcr-Abl tyrosine kinase inhibitors. XVIII Convegno Nazionale della Divisione di Chimica Farmaceutica della Società Chimica Italiana: ChietiPescara, Italy, September 16-20, 2007; Abs. P-113.